Exploring Candidate Biomarkers for Rheumatoid Arthritis Through Cardiovascular and Cardiometabolic Serum Proteome Profiling

Introduction: RA patients are at higher risk of cardiovascular disease, influenced by therapies. Studying their cardiovascular and cardiometabolic proteome can unveil biomarkers and insights into related biological pathways.

Methods: This study included two cohorts of RA patients: newly diagnosed individuals (n=25) and those with established RA (disease duration >25 years, n=25). Both cohorts were age and sex-matched with a control group (n=25). Additionally, a longitudinal investigation was conducted on a cohort of 25 RA patients treated with methotrexate and another cohort of 25 RA patients treated with tofacitinib for 6 months. Clinical and analytical variables were recorded, and serum profiling of 184 proteins was performed using the Olink technology platform.

Results: RA patients exhibited elevated levels of 75 proteins that might be associated with cardiovascular disease. In addition, 24 proteins were increased in RA patients with established disease. Twenty proteins were commonly altered in both cohorts of RA patients. Among these, elevated levels of CTSL1, SORT1, SAA4, TNFRSF10A, ST6GAL1 and CCL18 discriminated RA patients and HDs with high specificity and sensitivity. Methotrexate treatment significantly reduced the levels of 13 proteins, while tofacitinib therapy modulated the expression of 10 proteins. These reductions were associated with a decrease in DAS28. Baseline levels of SAA4 and high levels of BNP were associated to the non-response to methotrexate. Changes in IL6 levels were specifically linked to the response to methotrexate. Regarding tofacitinib, differences in baseline levels of LOX1 and CNDP1 were noted between non-responder and responder RA patients. In addition, response to tofacitinib correlated with changes in SAA4 and TIMD4 levels.

Conclusion: In summary, this study pinpoints molecular changes linked to cardiovascular disease in RA and proposes candidate protein biomarkers for distinguishing RA patients from healthy individuals. It also highlights how methotrexate and tofacitinib impact these proteins, with distinct alterations corresponding to each drug's response, identifying potential candidates, as SAA4, for the response to these therapies.

Citing Articles

miR-432-5p Targeting SORT1 to Protect Artery Smooth Muscle Cells and Inhibit Coronary Artery Disease.

Chen J, Liu F, Meng X Biochem Genet. 2024; .

PMID: 39730974 DOI: 10.1007/s10528-024-10998-w.

A targeted proteomics screen reveals serum and synovial fluid proteomic signature in patients with gout.

Huang Z, Zhong X, Zhang Y, Li X, Liu M, Huang Y Front Immunol. 2024; 15:1468810.

PMID: 39611154 PMC: 11602490. DOI: 10.3389/fimmu.2024.1468810.

References

Scherer H, van der Woude D, Ioan-Facsinay A, El Bannoudi H, Trouw L, Wang J . Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 2010; 62(6):1620-9. DOI: 10.1002/art.27414. View

Yang C, Ding H, Yu M, Zhou F, Han C, Liang R . proBDNF/p75NTR promotes rheumatoid arthritis and inflammatory response by activating proinflammatory cytokines. FASEB J. 2022; 36(3):e22180. DOI: 10.1096/fj.202101558R. View

Filbin M, Mehta A, Schneider A, Kays K, Guess J, Gentili M . Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med. 2021; 2(5):100287. PMC: 8091031. DOI: 10.1016/j.xcrm.2021.100287. View

Zheng Y, Wang L, Zhang W, Xu H, Chang X . Transgenic mice over-expressing carbonic anhydrase I showed aggravated joint inflammation and tissue destruction. BMC Musculoskelet Disord. 2012; 13:256. PMC: 3575273. DOI: 10.1186/1471-2474-13-256. View

Charles-Schoeman C, Buch M, Dougados M, Bhatt D, Giles J, Ytterberg S . Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL.... Ann Rheum Dis. 2022; 82(1):119-129. PMC: 9811099. DOI: 10.1136/ard-2022-222259. View

Arias de la Rosa I, Escudero-Contreras A, Rodriguez-Cuenca S, Ruiz-Ponce M, Jimenez-Gomez Y, Ruiz-Limon P . Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. J Intern Med. 2018; 284(1):61-77. DOI: 10.1111/joim.12743. View

Conaghan P, Ostergaard M, Troum O, Bowes M, Guillard G, Wilkinson B . Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. Arthritis Res Ther. 2019; 21(1):214. PMC: 6805378. DOI: 10.1186/s13075-019-2000-1. View

Morel J, Audo R, Hahne M, Combe B . Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem. 2005; 280(16):15709-18. DOI: 10.1074/jbc.M414469200. View

Patel K, Strong A, Tohyama J, Jin X, Morales C, Billheimer J . Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis. Circ Res. 2015; 116(5):789-96. PMC: 4602371. DOI: 10.1161/CIRCRESAHA.116.305811. View

10.

Jones M . IgG and leukocytes: Targets of immunomodulatory α2,6 sialic acids. Cell Immunol. 2018; 333:58-64. PMC: 6167213. DOI: 10.1016/j.cellimm.2018.03.014. View

11.

Deutsch E, Omenn G, Sun Z, Maes M, Pernemalm M, Palaniappan K . Advances and Utility of the Human Plasma Proteome. J Proteome Res. 2021; 20(12):5241-5263. PMC: 9469506. DOI: 10.1021/acs.jproteome.1c00657. View

12.

Chung C, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A . Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2007; 196(2):756-63. DOI: 10.1016/j.atherosclerosis.2007.01.004. View

13.

Meusch U, Klingner M, Mathar C, Malysheva O, Baerwald C, Rossol M . Brief Report: Autocrine Cytokine-Mediated Deficiency of TRAIL-Induced Monocyte Apoptosis in Rheumatoid Arthritis. Arthritis Rheumatol. 2015; 67(7):1760-5. DOI: 10.1002/art.39138. View

14.

Weitoft T, Larsson A, Manivel V, Lysholm J, Knight A, Ronnelid J . Cathepsin S and cathepsin L in serum and synovial fluid in rheumatoid arthritis with and without autoantibodies. Rheumatology (Oxford). 2015; 54(10):1923-8. DOI: 10.1093/rheumatology/keu486. View

15.

Seok A, Lee H, Lee S, Lee J, Mun S, Park A . Identification and Validation of SAA4 as a Rheumatoid Arthritis Prescreening Marker by Liquid Chromatography Tandem-mass Spectrometry. Molecules. 2017; 22(5). PMC: 6154608. DOI: 10.3390/molecules22050805. View

16.

Hloch K, Dosedel M, Duintjer Tebbens J, Zaloudkova L, Medkova H, Vlcek J . Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment. Front Pharmacol. 2021; 12:703279. PMC: 8602828. DOI: 10.3389/fphar.2021.703279. View

17.

van Lieshout A, Fransen J, Flendrie M, Eijsbouts A, van den Hoogen F, van Riel P . Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis. Ann Rheum Dis. 2007; 66(10):1334-8. PMC: 1994323. DOI: 10.1136/ard.2006.066084. View

18.

Figus F, Piga M, Azzolin I, McConnell R, Iagnocco A . Rheumatoid arthritis: Extra-articular manifestations and comorbidities. Autoimmun Rev. 2021; 20(4):102776. DOI: 10.1016/j.autrev.2021.102776. View

19.

Akgul O, Di Cesare Mannelli L, Vullo D, Angeli A, Ghelardini C, Bartolucci G . Discovery of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Management of Rheumatoid Arthritis. J Med Chem. 2018; 61(11):4961-4977. DOI: 10.1021/acs.jmedchem.8b00420. View

20.

Schneider P, Thome M, Burns K, Bodmer J, Hofmann K, Kataoka T . TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity. 1998; 7(6):831-6. DOI: 10.1016/s1074-7613(00)80401-x. View